Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
Conference Call Information
To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 8585078. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-host-conference-call-to-review-updated-clinical-data-for-pralsetinib-in-ret-altered-cancers-on-friday-may-29-2020-301064933.html
SOURCE
Investor and Media Contact, Jim Baker, 617-844-8236, media@blueprintmedicines.com; Investor Contact: Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com